← Back to headlines
BMO Reiterates Incyte Stock Rating Following CMS Pricing Agreement
BMO has reaffirmed its rating on Incyte stock, pointing to the strategic implications of the recent CMS pricing agreement for the biopharmaceutical company's pipeline.
1 Sept, 14:00 — 1 Sept, 14:00
Sources
Showing 1 of 1 sources
Related Stories
Honda Orders $9 Billion Supplier Cost Cuts to Counter Chinese EV Rivals
36m ago
US-Iran Conflict Intensifies with Retaliatory Strikes and Rising Energy Prices
39m ago
Apple Appoints John Ternus as CEO Amid Leadership Transition and Strategic Shift
41m ago
Nestlé to Sell Vitamins Business to Financial Investor for $1 Billion
57m ago